VY1706 first in human study in early Alzheimer's Disease is a multicenter dose escalation study
Male or female participants aged 55 to 80 years (inclusive) at Screening or aged 30 to 80 years (inclusive) if presence of a historically documented dominantly inherited mutation associated with monogenic AD.
Clinical diagnosis of mild cognitive impairment (MCI) due to AD or mild AD with MMSE 18-30 and CDR Global score of 0.5-1.
Apart from the clinical diagnosis of early AD, participant must be in good health as determined by the Investigator.
If the participant is receiving an approved symptomatic AD treatment, such as acetylcholinesterase or NMDA inhibitors, the participant must be on a stable dose for at least 8 weeks prior to Screening and until Day 1.
Seropositive for anti-AAV9 antibodies at Screening.
History of transient ischemic attack or stroke or any unexplained loss of consciousness within 1 year prior to Screening.
History of seizures within 10 years prior to Screening or history of epileptic syndrome (except for history of febrile seizures in childhood).
Presence of a clinically significant uncontrolled medical disorder that may compromise the participant's safety or their ability to complete all of the study assessments.